Avinger, Inc.

400 Chesapeake Dr.
Redwood City
CA
94063
United States

Show jobs for this employer

10 articles with Avinger, Inc.

  • Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today provided an update on the expansion of its intellectual property portfolio in 2020.

  • Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced full commercial launch of its Tigereye; image-guided chronic total occlusion (CTO) crossing system. With the initiation of full commercial launch, current and prospective accounts throughout the US and Germany

  • Avinger, Inc., a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease, announced that its executive team will participate in the H.C. Wainwright Bioconnect 2021 Conference taking place virtually January 11-14, 2021.

  • Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced results of its annual meeting of stockholders (the "Annual Meeting"), concluded on December 23, 2020.

  • Scheduled to Reconvene December 23, 2020 Avinger Strongly Encourages Stockholders to Immediately Vote FOR Proposal 3

  • Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today provided an update on the limited launch of its Tigereye™ next generation image-guided chronic total occlusion (CTO) crossing system

  • Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the company has received an extension until May 19, 2021 to regain compliance with the Nasdaq minimum bid price requirement for continued listing.

  • Avinger, Inc. today reported results for the third quarter ended September 30, 2020.

  • Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the commercial launch of its Lumivascular products and completion of its first patient cases in Israel.

  • Avinger, Inc., a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease, announced that it will release its financial results for the third quarter 2020 after the close of trading on Tuesday, November 10, 2020.